Skip to main content

Profound Medical Corp(PROF-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low6.76
Day High7.01
Open:6.96
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Profound Medical Schedules First-Quarter 2026 Earnings Release
GlobeNewswire
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
Tipranks
Profound Medical to Present Business Update at Conference
GlobeNewswire
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Tipranks
Profound Medical Showcases TULSA-PRO at Key Radiology Meeting
GlobeNewswire
Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
Tipranks
Profound Medical Marks Key TULSA Milestone as Texas Prostate Tops 100 Procedures
GlobeNewswire
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
Tipranks
Lake Street Keeps Their Buy Rating on Profound Medical (PRN)
Tipranks
Profound Medical Trial Shows TULSA Improves Prostate Cancer Outcomes
Tipranks
Profound Medical reports CAPTAIN trial meets primary safety endpoint
GlobeNewswire
CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
Tipranks
Profound Medical Announces Board Resignation and New Appointment
Tipranks
Profound Medical to Present First CAPTAIN Trial Results and Steps Up Investor Outreach
GlobeNewswire
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
Tipranks
Profound Medical Earnings Call Maps Path to Profit
Tipranks
Profound Medical (PRN) Gets a Buy from Lake Street
Tipranks
Stifel Nicolaus Sticks to Its Buy Rating for Profound Medical (PRN)
Tipranks
Profound Medical Posts Record Q4 Revenue as TULSA-PRO Adoption and Global Expansion Accelerate
GlobeNewswire
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
Tipranks
Profound Medical Schedules Q4 and 2025 Results Call
Tipranks
Profound Medical Earns INOVAIT Award, Accelerates TULSA Expansion
GlobeNewswire
Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow
GlobeNewswire
Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease
Tipranks
Profound Medical Marks 500th Sonalleve Procedure Milestone
GlobeNewswire
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health
Tipranks
Profound Medical to Engage Investors at February Life Sciences Conferences
GlobeNewswire
Profound Medical Announces Upcoming Investor Events
Tipranks
Profound Medical Expands TULSA-PRO Use at Mount Sinai
GlobeNewswire
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
Tipranks
Profound Medical Exceeds 2025 TULSA-PRO Installation Target and Grows Sales Pipeline
GlobeNewswire
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal

Profile

Profound Medical Corp. is a medical technology company. It is focused on a therapeutics platform which provides the precision of real-time Magnetic Resonance Imaging technology for the incision-free ablation of diseased tissue. The company principally commercialized the TULSA-PRO(R) and Sonalleve(R) platforms. Profound Medical Corp. is based in Mississauga, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.